Be the industry leader for the treatment of Gut Microbiota alteration (so-called dysbiosis) using patient-specific microbiotherapy in patients with serious medical conditions.
Our initial goal is to develop a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments. Our revolutionary and rapid approach will contribute to the evolution of treatment therapies in oncology.
Founded at the end of 2014, MaaT Pharma (Microbiota as a Therapy) is a clinical-stage biotech company revolutionizing and shaping a new approach to therapies to treat serious diseases linked to gut microbiota imbalances.
We believe that another approach is possible when it comes to treating gut microbiota alteration. This is why our team has been working on Fecal Microbiota Transfer (FMT) standardized processes and dedicated products that will be a critical addition to the current therapeutic arsenal. With our breakthrough proprietary platforms (GMP Fecal Microbiome Transfer platform and gΛt Print, our in-house data science platform), we are creating FMT-based drugs for patients suffering from severe diseases, with a focus primarily on blood cancer.
We are currently developing patient-friendly solutions (oral form), ready for clinical assessment, aimed at improving overall survival, reducing infectious episodes, reducing gastrointestinal complications and hindering Multidrug-resistant Bacteria.
MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
• Phase II proof-of-concept clinical trial in 21 centers of MaaT Pharma’s lead product, MaaT013, for treatment of patients with corticosteroid-refractory acute Graft-versus-Host Disease (GvHD). • MaaT013 has the potential to be a first in class therapy for acute...
Hervé Affagard live on Europe1 Label Entreprise talking about the company, our future and perspective, but mostly describing how we restore gut microbiota with Fecal Microbiota Transfer.